| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology, Vol 135, 834-840, Copyright © 1994 by Endocrine Society
ARTICLES |
M Lombes, S Kenouch, A Souque, N Farman and ME Rafestin-Oblin
INSERM U-246, UER Xavier BICHAT, Paris, France.
To investigate the mechanisms involved in the in vivo aldosterone selectivity of the mineralocorticoid receptor (MR), we studied the respective contribution of the receptor and the enzyme 11 beta- hydroxysteroid dehydrogenase (11HSD), which converts glucocorticoids into inactive metabolites. Using a cotransfection assay in CV-1 cells, aldosterone activated mouse mammary tumor virus promoter through human MR (hMR) with an ED50 of 0.01 nM. An at least 100-fold higher concentration of cortisol (F), corticosterone (B), or dexamethasone was required to obtain half-maximum transactivation, indicating a functional preference of hMR for aldosterone over glucocorticoids. The catalytic activity of 11HSD was analyzed using HPLC by measuring the tritiated metabolites produced in CV-1 and COS cells. Both cell types displayed a significant dehydrogenase activity (20 fmol/10 min.10(3) cells) inhibitable by carbenoxolone, but no detectable reductase activity. In this model, B was more rapidly metabolized than F. Carbenoxolone treatment of hMR-transfected CV-1 cells did not result in a shift of the dose-response transactivation curves of B and F toward lower concentrations, ruling out the implication of 11HSD in the aldosterone MR selectivity of these conditions. Despite similar affinity constants of aldosterone and glucocorticoids for the hMR, kinetic experiments showed that the off-rate of aldosterone from hMR was 5 times lower than that of glucocorticoids, pointing to an intrinsic discriminating property of the receptor. Therefore, we propose that in addition to 11HSD, MR plays an active role in the mechanism of aldosterone selectivity.
This article has been cited by other articles:
![]() |
G. A. Molnar, C. Lindschau, G. Dubrovska, P. R. Mertens, T. Kirsch, M. Quinkler, M. Gollasch, S. Wresche, F. C. Luft, D. N. Muller, et al. Glucocorticoid-Related Signaling Effects in Vascular Smooth Muscle Cells Hypertension, May 1, 2008; 51(5): 1372 - 1378. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Pascual-Le Tallec and M. Lombes The Mineralocorticoid Receptor: A Journey Exploring Its Diversity and Specificity of Action Mol. Endocrinol., September 1, 2005; 19(9): 2211 - 2221. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Pascual-Le Tallec, F. Simone, S. Viengchareun, G. Meduri, M. J. Thirman, and M. Lombes The Elongation Factor ELL (Eleven-Nineteen Lysine-Rich Leukemia) Is a Selective Coregulator for Steroid Receptor Functions Mol. Endocrinol., May 1, 2005; 19(5): 1158 - 1169. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Sartorato, F. Cluzeaud, J. Fagart, S. Viengchareun, M. Lombes, and M.-C. Zennaro New Naturally Occurring Missense Mutations of the Human Mineralocorticoid Receptor Disclose Important Residues Involved in Dynamic Interactions with Deoxyribonucleic Acid, Intracellular Trafficking, and Ligand Binding Mol. Endocrinol., September 1, 2004; 18(9): 2151 - 2165. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Pascual-Le Tallec, O. Kirsh, M.-C. Lecomte, S. Viengchareun, M.-C. Zennaro, A. Dejean, and M. Lombes Protein Inhibitor of Activated Signal Transducer and Activator of Transcription 1 Interacts with the N-Terminal Domain of Mineralocorticoid Receptor and Represses Its Transcriptional Activity: Implication of Small Ubiquitin-Related Modifier 1 Modification Mol. Endocrinol., December 1, 2003; 17(12): 2529 - 2542. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-E. Rafestin-Oblin, J. Fagart, A. Souque, C. Seguin, M. Bens, and A. Vandewalle 11beta -Hydroxyprogesterone Acts as a Mineralocorticoid Agonist in Stimulating Na+ Absorption in Mammalian Principal Cortical Collecting Duct Cells Mol. Pharmacol., December 1, 2002; 62(6): 1306 - 1313. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kitagawa, J. Yanagisawa, H. Fuse, S. Ogawa, Y. Yogiashi, A. Okuno, H. Nagasawa, T. Nakajima, T. Matsumoto, and S. Kato Ligand-Selective Potentiation of Rat Mineralocorticoid Receptor Activation Function 1 by a CBP-Containing Histone Acetyltransferase Complex Mol. Cell. Biol., June 1, 2002; 22(11): 3698 - 3706. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Yoshikawa, Y. Makino, K. Okamoto, C. Morimoto, I. Makino, and H. Tanaka Distinct Interaction of Cortivazol with the Ligand Binding Domain Confers Glucocorticoid Receptor Specificity. CORTIVAZOL IS A SPECIFIC LIGAND FOR THE GLUCOCORTICOID RECEPTOR J. Biol. Chem., February 8, 2002; 277(7): 5529 - 5540. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ngarmukos and R. J. Grekin Nontraditional aspects of aldosterone physiology Am J Physiol Endocrinol Metab, December 1, 2001; 281(6): E1122 - E1127. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-C. Zennaro, A. Souque, S. Viengchareun, E. Poisson, and M. Lombes A New Human MR Splice Variant Is a Ligand-Independent Transactivator Modulating Corticosteroid Action Mol. Endocrinol., September 1, 2001; 15(9): 1586 - 1598. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Karssen, O. C. Meijer, I. C. J. van der Sandt, P. J. Lucassen, E. C. M. de Lange, A. G. de Boer, and E. R. de Kloet Multidrug Resistance P-Glycoprotein Hampers the Access of Cortisol But Not of Corticosterone to Mouse and Human Brain Endocrinology, June 1, 2001; 142(6): 2686 - 2694. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Farman and M.-E. Rafestin-Oblin Multiple aspects of mineralocorticoid selectivity Am J Physiol Renal Physiol, February 1, 2001; 280(2): F181 - F192. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Le Menuet, S. Viengchareun, P. Penfornis, F. Walker, M.-C. Zennaro, and M. Lombes Targeted Oncogenesis Reveals a Distinct Tissue-specific Utilization of Alternative Promoters of the Human Mineralocorticoid Receptor Gene in Transgenic Mice J. Biol. Chem., March 10, 2000; 275(11): 7878 - 7886. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. M. Rogerson, N. Dimopoulos, P. Sluka, S. Chu, A. J. Curtis, and P. J. Fuller Structural Determinants of Aldosterone Binding Selectivity in the Mineralocorticoid Receptor J. Biol. Chem., December 17, 1999; 274(51): 36305 - 36311. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Delcayre and J.-S. Silvestre Aldosterone and the heart: towards a physiological function? Cardiovasc Res, July 1, 1999; 43(1): 7 - 12. [Full Text] [PDF] |
||||
![]() |
R. C. Wilson, S. Dave-Sharma, J.-Q. Wei, V. R. Obeyesekere, K. Li, P. Ferrari, Z. S. Krozowski, C. H. L. Shackleton, L. Bradlow, T. Wiens, et al. A genetic defect resulting in mild low-renin hypertension PNAS, August 18, 1998; 95(17): 10200 - 10205. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sato, J.-P. Liu, and J. W. Funder Aldosterone Rapidly Represses Protein Kinase C Activity in Neonatal Rat Cardiomyocytes in Vitro Endocrinology, August 1, 1997; 138(8): 3410 - 3416. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Morineau, A. Boudi, A. Barka, M. Gourmelen, F. Degeilh, N. Hardy, A. Al-Halnak, H. Soliman, J. P. Gosling, R. Julien, et al. Radioimmunoassay of cortisone in serum, urine, and saliva to assess the status of the cortisol–cortisone shuttle Clin. Chem., August 1, 1997; 43(8): 1397 - 1407. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Lim-Tio, M.-C. Keightley, and P. J. Fuller Determinants of Specificity of Transactivation by the Mineralocorticoid or Glucocorticoid Receptor Endocrinology, June 1, 1997; 138(6): 2537 - 2543. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. C. White, T. Mune, and A. K. Agarwal 11{beta}-Hydroxysteroid Dehydrogenase and the Syndrome of Apparent Mineralocorticoid Excess Endocr. Rev., February 1, 1997; 18(1): 135 - 156. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |